Iothalamic acid

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Iothalamic acid
Accession Number
DB09133
Type
Small Molecule
Groups
Approved
Description

Iothalamic acid is an iodine containing organic anion used as a diagnostic contrast agent.

Structure
Thumb
Synonyms
  • 1-deoxy-1-(methylamino)-D-glucitol 5-acetamido-2,4,6 triiodo-N-methylisophthalamate
  • Iotalamic acid
  • Iothalamate
  • Iothalamic acid
External IDs
MI 216 / MI-216 / MI216
Product Ingredients
IngredientUNIICASInChI Key
Iothalamate meglumineXUW72GOP7W13087-53-1VLHUSFYMPUDOEL-WZTVWXICSA-N
Iothalamate sodiumKDN276D83N1225-20-3WCIMWHNSWLLELS-UHFFFAOYSA-M
Iothalamate sodium I-12531J5U3Q9ZN17692-74-9Not applicable
Sodium IothalamateNot AvailableNot AvailableNot applicable
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ConrayInjection600 mg/1mLIntravascularLiebel-Flarsheim Company LLC2003-10-14Not applicableUs
Conray 30Solution300 mgIntravascularLiebel Flarsheim Company Llc1992-01-292018-03-14Canada
Conray 30Injection300 mg/1mLIntravascularLiebel-Flarsheim Company LLC2012-03-262018-09-15Us
Conray 325SolutionIntravenousTyco Healthcare1979-12-312010-01-12Canada
Conray 400Injection668 mg/1mLIntravascularMallinckrodt1998-01-012009-12-31Us
Conray 400Solution66.8 %IntravenousTyco Healthcare1964-12-312010-01-12Canada
Conray 43Solution430 mgIntravascularLiebel Flarsheim Company Llc1980-12-312018-05-07Canada
Conray 43Injection430 mg/1mLIntravascularLiebel-Flarsheim Company LLC2010-10-11Not applicableUs
Conray 60SolutionIntravascularLiebel Flarsheim Company Llc1951-12-31Not applicableCanada
Cysto Conray Inj 43%LiquidUrethralMallinckrodt1973-12-312001-03-15Canada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
VascorayIothalamate meglumine (520 mg) + Iothalamate sodium (260 mg)SolutionIntra-arterial; IntravenousTyco Healthcare1986-12-182010-01-12Canada
VascorayIothalamate meglumine (520 mg) + Iothalamate sodium (260 mg)SolutionIntra-arterial; IntravenousTyco Healthcare1986-12-182010-01-12Canada
Categories
UNII
16CHD79MIX
CAS number
2276-90-6
Weight
Average: 613.916
Monoisotopic: 613.76964
Chemical Formula
C11H9I3N2O4
InChI Key
UXIGWFXRQKWHHA-UHFFFAOYSA-N
InChI
InChI=1S/C11H9I3N2O4/c1-3(17)16-9-7(13)4(10(18)15-2)6(12)5(8(9)14)11(19)20/h1-2H3,(H,15,18)(H,16,17)(H,19,20)
IUPAC Name
3-acetamido-2,4,6-triiodo-5-(methylcarbamoyl)benzoic acid
SMILES
CNC(=O)C1=C(I)C(C(O)=O)=C(I)C(NC(C)=O)=C1I

Pharmacology

Indication

Conray is indicated for use in excretory urography, cerebral angiography, peripheral arteriography, venography, arthrography, direct cholangiography, endoscopic retrograde cholangiopancreatography, contrast enhancement of computed tomographic brain images, cranial computerized angiotomography, intravenous digital subtraction angiography and arterial digital subtraction angiography. Conray may also be used for enhancement of computed tomographic scans performed for detection and evaluation of lesions in the liver, pancreas, kidneys, abdominal aorta, mediastinum, abdominal cavity and retroperitoneal space.

Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

Renal accumulation is sufficiently rapid that maximum radiographic density in the calyces and pelves occurs, in most instances, about 3 to 8 minutes after injection. In patients with impaired renal function, diagnostic opacification frequently is achieved only after prolonged periods.

Volume of distribution
Not Available
Protein binding

Iothalamate salts are poorly bound to serum albumin.

Metabolism
Not Available
Route of elimination

Following intravascular injection, Conray is rapidly transported through the circulatory system to the kidneys and is excreted unchanged in the urine by glomerular filtration. The liver and small intestine provide the major alternate route of excretion. In patients with severe renal impairment, the excretion of this contrast medium through the gallbladder and into the small intestine sharply increases.

Half life

In patients with normal renal function, the alpha and beta half-lives of Conray were approximately 10 and 90 minutes, respectively.

Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirAbacavir may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.
AcarboseAcarbose may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.
AceclofenacAceclofenac may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.
AcetaminophenAcetaminophen may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.
AcetazolamideAcetazolamide may increase the excretion rate of Iothalamic acid which could result in a lower serum level and potentially a reduction in efficacy.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.
AclidiniumAclidinium may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.
AcrivastineIothalamic acid may decrease the excretion rate of Acrivastine which could result in a higher serum level.
AcyclovirAcyclovir may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Drug
D01258
PubChem Compound
3737
PubChem Substance
310265048
ChemSpider
3606
ChEBI
31713
ChEMBL
CHEMBL1201300
Drugs.com
Drugs.com Drug Page
Wikipedia
Iotalamic_acid
ATC Codes
V08AA04 — Iotalamic acid
AHFS Codes
  • 36:68.00 — Roentgenography

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
InjectionIntravascular600 mg/1mL
InjectionIntravascular300 mg/1mL
SolutionIntravascular300 mg
SolutionIntravenous
InjectionIntravascular668 mg/1mL
SolutionIntravenous66.8 %
InjectionIntravascular430 mg/1mL
SolutionIntravascular430 mg
SolutionIntravascular
LiquidUrethral
InjectionUreteral172 mg/1mL
SolutionUrethral172 mg
InjectionIntravenous1 mg/1
Injection, solutionIntravenous0.275 mCi/1mL
SolutionIntra-arterial; Intravenous
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.123 mg/mLALOGPS
logP2.27ALOGPS
logP2.73ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)2.13ChemAxon
pKa (Strongest Basic)-1.7ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area95.5 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity102.24 m3·mol-1ChemAxon
Polarizability38.58 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as acylaminobenzoic acid and derivatives. These are derivatives of amino benzoic acid derivatives where the amine group is N-acylated.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Acylaminobenzoic acid and derivatives
Alternative Parents
P-haloacetanilides / O-haloacetanilides / 2-halobenzoic acids / 4-halobenzoic acids / Halobenzoic acids / N-acetylarylamines / Benzoic acids / Benzamides / 1-carboxy-2-haloaromatic compounds / Benzoyl derivatives
show 11 more
Substituents
Acylaminobenzoic acid or derivatives / O-haloacetanilide / P-haloacetanilide / Haloacetanilide / Acetanilide / 2-halobenzoic acid or derivatives / 4-halobenzoic acid or derivatives / Halobenzoic acid or derivatives / 2-halobenzoic acid / 4-halobenzoic acid
show 30 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Drug created on September 29, 2015 16:06 / Updated on November 20, 2019 12:30